07:00 , Apr 28, 2008 |  BC Week In Review  |  Clinical News

Neu2000KL: Phase I final data

In a double-blind, placebo-controlled U.S. Phase I trial in 95 healthy volunteers, IV doses of up to 6,000 mg of Neu2000KL were well tolerated. There were no serious adverse events. Amkor Pharma Inc. , Seattle,...
07:00 , Apr 3, 2008 |  BC Innovations  |  Distillery Therapeutics

This Week in Therapeutics

This week in therapeutics Indication Target/marker /pathway Summary Licensing status Publication and contact information Neurology Multiple sclerosis (MS) Glutamate receptor (NMDA receptor) A study in mice suggests that a water-soluble fullerene derivative attached to NMDA...